Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679027 | 0.93 | KMT2A (0.48) | CTSLPTPN1SIRT2KMT2AHDAC1 | |
| SCHEMBL22117557 | 0.89 | CTSL (0.51) | CTSLSIRT2NPY4RPTGER4 | |
| SCHEMBL22117811 | 0.89 | CTSL (0.51) | CTSLSIRT2NPY4RPTGER4 | |
| SCHEMBL22117808 | 0.89 | CTSL (0.51) | CTSLSIRT2NPY4RPTGER4 | |
| SCHEMBL22117556 | 0.89 | CTSL (0.51) | CTSLSIRT2NPY4RPTGER4 | |
| SCHEMBL31679025 | 0.87 | KLK7 (0.50) | CTSLSIRT2NPY4R | |
| SCHEMBL22117377 | 0.86 | CTSL (0.49) | CTSLNPY4RPTGER4 | |
| SCHEMBL22117376 | 0.86 | CTSL (0.49) | CTSLNPY4RPTGER4 | |
| SCHEMBL31679020 | 0.86 | CTSL (0.53) | CTSLNPY4RPTGER4 | |
| SCHEMBL31679017 | 0.86 | CTSL (0.49) | CTSLSIRT2NPY4RPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | CTSL 1491/4885PTPN1 4613/4885SIRT2 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.